Logo image of DERM

JOURNEY MEDICAL CORP (DERM) Stock Fundamental Analysis

NASDAQ:DERM - Nasdaq - US48115J1097 - Common Stock - Currency: USD

7.48  +0.09 (+1.22%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DERM. DERM was compared to 198 industry peers in the Pharmaceuticals industry. DERM may be in some trouble as it scores bad on both profitability and health. DERM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DERM has reported negative net income.
In the past year DERM has reported a negative cash flow from operations.
In the past 5 years DERM reported 4 times negative net income.
In multiple years DERM reported negative operating cash flow during the last 5 years.
DERM Yearly Net Income VS EBIT VS OCF VS FCFDERM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of DERM (-18.28%) is better than 62.63% of its industry peers.
DERM has a Return On Equity (-73.11%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -18.28%
ROE -73.11%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DERM Yearly ROA, ROE, ROICDERM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

DERM has a Gross Margin of 56.71%. This is in the better half of the industry: DERM outperforms 65.15% of its industry peers.
In the last couple of years the Gross Margin of DERM has declined.
The Profit Margin and Operating Margin are not available for DERM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
DERM Yearly Profit, Operating, Gross MarginsDERM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for DERM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DERM Yearly Shares OutstandingDERM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
DERM Yearly Total Debt VS Total AssetsDERM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -0.11, we must say that DERM is in the distress zone and has some risk of bankruptcy.
DERM's Altman-Z score of -0.11 is in line compared to the rest of the industry. DERM outperforms 55.56% of its industry peers.
DERM has a Debt/Equity ratio of 1.24. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.24, DERM is doing worse than 71.72% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF N/A
Altman-Z -0.11
ROIC/WACCN/A
WACC10.47%
DERM Yearly LT Debt VS Equity VS FCFDERM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

A Current Ratio of 1.37 indicates that DERM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.37, DERM is not doing good in the industry: 75.76% of the companies in the same industry are doing better.
DERM has a Quick Ratio of 1.37. This is a bad value and indicates that DERM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of DERM (0.96) is worse than 77.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 0.96
DERM Yearly Current Assets VS Current LiabilitesDERM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for DERM have decreased strongly by -466.67% in the last year.
Looking at the last year, DERM shows a very negative growth in Revenue. The Revenue has decreased by -29.10% in the last year.
Measured over the past years, DERM shows a quite strong growth in Revenue. The Revenue has been growing by 9.96% on average per year.
EPS 1Y (TTM)-466.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-29.1%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%-10.73%

3.2 Future

The Earnings Per Share is expected to grow by 56.25% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 39.64% on average over the next years. This is a very strong growth
EPS Next Y72.5%
EPS Next 2Y72.43%
EPS Next 3Y56.25%
EPS Next 5YN/A
Revenue Next Year25.96%
Revenue Next 2Y39.67%
Revenue Next 3Y39.64%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DERM Yearly Revenue VS EstimatesDERM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
DERM Yearly EPS VS EstimatesDERM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DERM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DERM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DERM Price Earnings VS Forward Price EarningsDERM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DERM Per share dataDERM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as DERM's earnings are expected to grow with 56.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.43%
EPS Next 3Y56.25%

More info and screens

0

5. Dividend

5.1 Amount

DERM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JOURNEY MEDICAL CORP

NASDAQ:DERM (4/23/2025, 8:00:01 PM)

7.48

+0.09 (+1.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26 2025-03-26/amc
Earnings (Next)05-13 2025-05-13
Inst Owners25.49%
Inst Owner Change0%
Ins Owners7.91%
Ins Owner Change-1.32%
Market Cap127.91M
Analysts82
Price Target10.07 (34.63%)
Short Float %1.1%
Short Ratio2.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)22.64%
Min EPS beat(2)-12.99%
Max EPS beat(2)58.28%
EPS beat(4)1
Avg EPS beat(4)-23.03%
Min EPS beat(4)-121.11%
Max EPS beat(4)58.28%
EPS beat(8)3
Avg EPS beat(8)56.31%
EPS beat(12)4
Avg EPS beat(12)32.83%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.18%
Min Revenue beat(2)-6.06%
Max Revenue beat(2)-0.31%
Revenue beat(4)1
Avg Revenue beat(4)-2.71%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)4.92%
Revenue beat(8)3
Avg Revenue beat(8)9.6%
Revenue beat(12)4
Avg Revenue beat(12)4%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.25%
PT rev (3m)-1.25%
EPS NQ rev (1m)-137.5%
EPS NQ rev (3m)-137.5%
EPS NY rev (1m)-205.56%
EPS NY rev (3m)-205.56%
Revenue NQ rev (1m)-3.12%
Revenue NQ rev (3m)-3.12%
Revenue NY rev (1m)-7.72%
Revenue NY rev (3m)-7.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.28
P/FCF N/A
P/OCF N/A
P/B 6.37
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS3.28
BVpS1.17
TBVpS-0.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.28%
ROE -73.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.71%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
F-Score2
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 438.08%
Cap/Sales 26.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 0.96
Altman-Z -0.11
F-Score2
WACC10.47%
ROIC/WACCN/A
Cap/Depr(3y)346.04%
Cap/Depr(5y)304.38%
Cap/Sales(3y)20.06%
Cap/Sales(5y)15.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-466.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y72.5%
EPS Next 2Y72.43%
EPS Next 3Y56.25%
EPS Next 5YN/A
Revenue 1Y (TTM)-29.1%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%-10.73%
Revenue Next Year25.96%
Revenue Next 2Y39.67%
Revenue Next 3Y39.64%
Revenue Next 5YN/A
EBIT growth 1Y-1794.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year152.2%
EBIT Next 3Y82.76%
EBIT Next 5YN/A
FCF growth 1Y-10152.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-274.18%
OCF growth 3YN/A
OCF growth 5YN/A